出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2022年2月
無針注射システム市場 : テクノロジー（ジェット、スプリング、マイクロアレイパッチ）、製品別（プレフィルド、フィル可能）、医薬品の種類（液体、粉末）、用途（ワクチン接種、皮膚科）、エンドユーザー（病院、ホームケア）- 2026年までの世界予測
Needle-Free Injection System Market by Technology (Jet, Spring, Micro-array Patch), by Product (Prefilled, Fillable), Type of Medication (Liquid, Powder), Application (Vaccination, Dermatology), End Users (Hospital, Homecare) – Global Forecast to 2026
| ページ数 | 232 |
| 図表数 | 219 |
| 種別 | 英文調査報告書 |
| 価格 |
MarketsandMarkets expects the needle-free injection system market is projected to reach USD 272 million by 2026 from USD 124 million in 2021, at a CAGR of 17.0% from 2020 to 2026. Growth in this market is mainly driven by technological advancements, increasing demand for self-injection devices, and the rising incidence of chronic diseases. With the rising geriatric population and the increasing prevalence of chronic diseases, the patient volume has increased significantly globally. This, in turn, is creating a greater demand for advanced and effective treatment approaches, including the use of needle-free injection systems. Moreover, the high adoption of advanced drug delivery technologies across the globe is supporting the growth of this market. On the other hand, limitations with large volume and intravenous administration systems are the key factors restraining the growth of the market
In this report, the needle-free injection system market is segmented on the basis of product, type, application, technology, site of delivery, end user, and region.
“fillable needle-free injectors segment accounted for the largest share in the needle-free injection system market.”
Based on product, the needle-free injection system market is segmented into fillable and pre-filled needle-free injectors. In 2020, the fillable needle-free injectors accounted for the larger share of 63.4% of the needle-free injection system market. This product segment is projected to reach USD 179.7 million by 2026 from 79.4 million in 2021, at a CAGR of 17.7 % during the forecast period. The large share of this segment can be attributed to the increasing application of needle-free injections in vaccination, insulin, and other drug delivery.
“Jet-based needle-free injectors segment accounted for the largest share in the needle-free injection system market.”
On the basis of technology, the needle-free injection system market can be segmented into jet-based, spring-based, microarray patches and other injectors. In 2020, the jet-based needle-free injectors segment is expected to command the largest share of 67.4% of the global needle-free injection system devices market by technology. This segment is projected to reach USD 196.9 million by 2026 from USD 71.4 million in 2020, at a CAGR of 18.3% during the forecast period. The large share of this segment can be attributed to benefits associated with this technology, including rapid drug administration, improved dosage accuracy, better diffusion into the tissue, and a faster response rate.
“ liquid-based injectors segment accounted for the largest share in the needle-free injection system market.”
Based on the type, the needle-free injection system market is segmented into liquid-based, powder-based and projectile/depot-based needle-free injectors. The liquid-based segment accounted for the largest share of 70.9% of the needle-free injection system market in 2020. The large share of this segment can be attributed to the ability of a liquid jet, which is stronger enough to penetrate the skin and the underlying fat layer without harming the skin or the integrity of the drug molecule.
“subcutaneous injectors segment accounted for the largest share in the needle-free injection system market.”
Based on site of delivery, the needle-free injection system market is segmented into subcutaneous, intramuscular and intradermal. In 2020, the subcutaneous injectors segment is estimated to account for the largest share of 48% of the needle-free injection system market by the site of delivery. The higher growth of this segment is due to its greater effectiveness as the drug moves into the capillaries when it is injected and from there, it is carried to the bloodstream.
“Fillable segment accounted for the largest share in the needle-free injection system market.”
Based on applications, the needle-free injection system market is segmented into vaccine delivery, insulin delivery, oncology, pain management, dermatology, and other applications. In 2020, vaccine delivery is estimated to account for the largest share of 32.8% of the needle-free injection system market by application. The rising prevalence of chronic diseases and infectious diseases worldwide has increased the demand for vaccination in the considered year and the increasing demand for patient-centric care are the major factors driving the growth of the needle-free injection market by application.
“hospitals & clinics segment accounted for the largest share in the needle-free injection system market.”
Based on end users, the needle-free injection market is segmented into hospitals & clinics, home care settings, research laboratories, pharmaceutical and biotechnology companies, and other end users. The hospitals & clinics segment accounted for the largest market share of 61.0% in 2020. Factors such as technological advancements and an increase in demand for vaccination are driving the growth of the hospitals & clinics segment.
“North America accounted segment accounted for the largest share in the needle-free injection system market.”
On the basis of region, the needle-free injection system market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of 58% of the needle-free injection market, followed by Europe, the Asia Pacific (APAC), Latin America, and the Middle East & Africa. However, the APAC region is expected to grow at the highest CAGR of 18.7% during the forecast period. The rapidly developing healthcare industry in China and India, growth in the aging population, rising life expectancy, rising per capita income, increasing investments in the region by key market players, the expansion of private-sector hospitals & clinics to rural areas, the availability of low-cost labor for manufacturing, the presence of a favorable regulatory environment, and growing demand for self-injectable devices testing are supporting market growth in the APAC region.
Key Market Players :
The prominent players in global needle-free injection market include PharmaJet (US), Portal Instruments (US), Medical International Technology, Inc (MIT) (US), NuGen Medical Devices (Canada), Crossject SA (US), and Bioject Medical Technologies (US).
A breakdown of the primary participants (supply-side) for the needle-free injection system market referred to for this report is provided below:
• By Company Type: Tier 1–5%, Tier 2–15%, and Tier 3–80%
• By Designation: C-level–45%, Director Level–25%, and Others–30%
• By Region: North America–36%, Europe–26%, Asia Pacific–21%, Latin America- 10%, and Middle East and Africa– 7%
Research Coverage:
The market study covers the needle-free injection system market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by product, by type, by application, by technology, by site of delivery, by end user, and by region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants in this market and provide information regarding the closest approximations of the needle-free injection system market and its segments. This report will help stakeholders understand the competitive landscape, gain insights to position their businesses better, and plan suitable go-to-market strategies. The report will also help stakeholders in understanding the pulse of the market and gaining information on key market drivers, restraints, opportunities, and challenges.
目次
TABLE OF CONTENTS
1 INTRODUCTION (Page No. – 29)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 MARKETS COVERED–BY REGION
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. – 35)
2.1 RESEARCH APPROACH
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Breakdown of primaries
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 3 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2020)
FIGURE 4 SUPPLY SIDE ANALYSIS: NEEDLE-FREE INJECTION SYSTEM MARKET
FIGURE 5 TOP-DOWN APPROACH
FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NEEDLE-FREE INJECTION SYSTEM MARKET (2021– 2026)
FIGURE 7 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS OF THE NEEDLE-FREE INJECTION SYSTEM MARKET (2020)
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 KEY INDUSTRY INSIGHTS
2.5 LIMITATIONS
2.5.1 METHODOLOGY-RELATED LIMITATIONS
2.6 RISK ASSESSMENT
2.7 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY (Page No. – 48)
FIGURE 9 NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
FIGURE 10 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 11 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 12 NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2021 VS. 2026 (USD MILLION)
FIGURE 13 NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 14 NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE NEEDLE-FREE INJECTION SYSTEM MARKET
4 PREMIUM INSIGHTS (Page No. – 54)
4.1 NEEDLE-FREE INJECTION SYSTEM MARKET OVERVIEW
FIGURE 16 HIGH PREVALENCE OF INFECTIOUS DISEASES, GROWING INCIDENCE OF COMMUNICABLE DISEASES DUE TO NEEDLESTICK INJURIES, AND RISE IN DEMAND FOR SELF-INJECTION DEVICES TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION AND COUNTRY
FIGURE 17 VACCINATION ACCOUNTED FOR THE LARGEST SHARE IN ASIA PACIFIC
4.3 NEEDLE-FREE INJECTION SYSTEM MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATES DURING THE FORECAST PERIOD
4.4 NEEDLE-FREE INJECTION SYSTEM MARKET: DEVELOPING VS DEVELOPED COUNTRIES
FIGURE 19 DEVELOPING COUNTRIES TO OFFER HIGHER GROWTH
4.5 REGIONAL MIX: NEEDLE-FREE INJECTION SYSTEM MARKET
FIGURE 20 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. – 58)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 High prevalence of infectious diseases globally
FIGURE 21 PREVALENCE OF INFECTIOUS DISEASES WORLDWIDE
TABLE 2 PREVALENCE OF HIV WORLDWIDE (2017 VS. 2020)
5.2.1.2 Increasing incidence of communicable diseases due to needlestick injuries
5.2.1.3 Rise in demand for self-injection devices
5.2.1.4 Increased number of technological advancements
5.2.1.5 Reduction in injection system costs
5.2.2 RESTRAINTS
5.2.2.1 Higher cost of development as compared to conventional injection systems
5.2.2.2 Limitation with large volume and intravenous administration systems
5.2.3 OPPORTUNITIES
5.2.3.1 Rising demand for biosimilars and vaccination processes
5.2.3.2 Increasing number of emerging markets
5.2.4 CHALLENGES
5.2.4.1 Rise in need to ensure system sterility
5.2.4.2 Growth in alternative modes of drug delivery
5.3 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO IN NEEDLE-FREE INJECTION SYSTEM MARKET
FIGURE 22 IMPACT OF COVID-19 PANDEMIC ON ENTIRE NEEDLE-FREE INJECTION ECOSYSTEM (2020)- KEY HOT SPOTS OF ACTIVITY ARE HIGHLIGHTED PREVALENCE OF INFECTIOUS DISEASES WORLDWIDE
5.4 PRICING ANALYSIS
TABLE 3 AVERAGE SELLING PRICE OF NEEDLE-FREE INJECTORS IN NORTH AMERICA, BY APPLICATIONS, FOR 2020
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 23 SUPPLY CHAIN ANALYSIS: NEEDLE-FREE INJECTION SYSTEM MARKET (2020)
5.6 PATENT ANALYSIS
5.6.1 PATENT PUBLICATION TRENDS FOR NEEDLE-FREE INJECTION SYSTEM MARKET
FIGURE 24 GLOBAL PATENT PUBLICATION TRENDS IN NEEDLE-FREE INJECTION SYSTEM, 2016–2021
5.6.2 TOP APPLICANTS (COMPANIES) OF NEEDLE-FREE INJECTION SYSTEM PATENTS
FIGURE 25 TOP COMPANIES THAT APPLIED FOR NEEDLE-FREE INJECTION SYSTEM PATENTS, 2016–2021
5.6.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN NEEDLE-FREE INJECTION SYSTEM MARKET
FIGURE 26 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR NEEDLE-FREE INJECTION SYSTEM PATENTS, 2016–2021
5.7 VALUE CHAIN ANALYSIS
FIGURE 27 NEEDLE-FREE INJECTION SYSTEM MARKET: VALUE CHAIN ANALYSIS (2020)
5.8 TECHNOLOGY ANALYSIS
5.8.1 KEY TECHNOLOGY: JET-BASED NEEDLE-FREE INJECTORS
5.8.2 ADJACENT TECHNOLOGY: SPRING-BASED NEEDLE-FREE INJECTORS
5.8.3 MICROARRAY PATCH
5.8.4 OTHER TECHNOLOGIES
5.9 REGULATORY LANDSCAPE
TABLE 4 REGULATORY STANDARDS/APPROVALS REQUIRED FOR NEEDLE-FREE INJECTION PRODUCTS, BY COUNTRY/REGION
5.10 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 NEEDLE-FREE INJECTION SYSTEM: PORTER’S FIVE FORCES ANALYSIS
5.10.1 THREAT FROM NEW ENTRANTS
5.10.2 COMPETITIVE RIVALRY
5.10.3 BARGAINING POWER OF BUYERS
5.10.4 BARGAINING POWER OF SUPPLIERS
5.10.5 THREAT FROM SUBSTITUTES
6 NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT (Page No. – 76)
6.1 INTRODUCTION
TABLE 6 NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
6.2 FILLABLE NEEDLE-FREE INJECTORS
6.2.1 TREATMENT OF DISEASES THAT REQUIRE REGULAR ADMINISTRATION OF MEDICATION TO DRIVE MARKET GROWTH
TABLE 7 FILLABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3 PREFILLED NEEDLE-FREE INJECTORS
6.3.1 SELF-ADMINISTRATION OF DRUGS FOR TREATMENT TO DRIVE MARKET GROWTH
TABLE 8 PREFILLED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY (Page No. – 80)
7.1 INTRODUCTION
TABLE 9 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
7.2 JET-BASED NEEDLE-FREE INJECTORS
7.2.1 WIDE APPLICATIONS OF JET-BASED INJECTIONS TO DRIVE SEGMENT GROWTH
TABLE 10 JET-BASED NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 SPRING-BASED NEEDLE-FREE INJECTORS
7.3.1 LOW COST OF SPRING-BASED INJECTORS TO DRIVE MARKET GROWTH
TABLE 11 SPRING-BASED NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.4 MICRO-ARRAY PATCH
7.4.1 FUTURE DEMAND FOR VACCINES AND CONTRACEPTIVES MICRO-ARRAY PATCHES TO DRIVE MARKET GROWTH
TABLE 12 MICRO-ARRAY PATCH MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.5 OTHER TECHNOLOGIES
TABLE 13 OTHER TECHNOLOGIES NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE (Page No. – 86)
8.1 INTRODUCTION
TABLE 14 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
8.2 LIQUID-BASED NEEDLE-FREE INJECTORS
8.2.1 INCREASE IN VACCINATION FOR INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
TABLE 15 LIQUID-BASED NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 POWDER-BASED NEEDLE-FREE INJECTORS
8.3.1 REQUIREMENT OF STABLE DRUGS TO DRIVE MARKET GROWTH
TABLE 16 POWDER-BASED NEEDLE FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 PROJECTILE/DEPOT-BASED NEEDLE-FREE INJECTORS
8.4.1 USE OF INERT MATERIAL OR SELF MEDICAMENT TO DRIVE MARKET GROWTH
TABLE 17 PROJECTILE/DEPOT-BASED NEEDLE FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
9 NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY (Page No. – 91)
9.1 INTRODUCTION
TABLE 18 NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
9.2 SUBCUTANEOUS NEEDLE-FREE INJECTORS
9.2.1 PREFERENCE FOR ADMINISTERING DELICATE DRUGS FOR INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
TABLE 19 SUBCUTANEOUS NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
9.2.2 INTRAMUSCULAR NEEDLE-FREE INJECTORS
9.2.2.1 Increase in vaccination requirement to drive market growth
TABLE 20 INTRAMUSCULAR NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
9.2.3 INTRADERMAL NEEDLE-FREE INJECTORS
9.2.3.1 Use of inert material or self medicament to drive market growth
TABLE 21 INTRADERMAL NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
10 NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION (Page No. – 96)
10.1 INTRODUCTION
TABLE 22 NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
10.2 VACCINE DELIVERY
10.2.1 COST-EFFECTIVENESS AND RISE OF PREVENTIVE MEASURES TO DRIVE GROWTH IN VACCINES DELIVERY
TABLE 23 NEEDLE-FREE INJECTION SYSTEM MARKET FOR VACCINE DELIVERY, BY COUNTRY, 2019–2026 (USD MILLION)
10.3 INSULIN DELIVERY
10.3.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET GROWTH
TABLE 24 NEEDLE-FREE INJECTION SYSTEM MARKET FOR INSULIN DELIVERY, BY COUNTRY, 2019–2026 (USD MILLION)
10.4 ONCOLOGY
10.4.1 RISE IN CANCER PREVALENCE AND AVAILABILITY OF CANCER TREATMENT TO DRIVE MARKET GROWTH
TABLE 25 NEEDLE-FREE INJECTION SYSTEM MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
10.5 PAIN MANAGEMENT
10.5.1 INCREASED PREVALENCE AND TREATMENT OF CHRONIC DISEASES TO DRIVE MARKET GROWTH
TABLE 26 NEEDLE-FREE INJECTION SYSTEM MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2019–2026 (USD MILLION)
10.6 DERMATOLOGY
10.6.1 INCREASED DERMATOLOGY-BASED TREATMENTS AND SURGERIES TO DRIVE MARKET GROWTH
TABLE 27 NEEDLE-FREE INJECTION SYSTEM MARKET FOR DERMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
10.7 OTHER APPLICATIONS
TABLE 28 NEEDLE-FREE INJECTION SYSTEM MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
11 NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER (Page No. – 104)
11.1 INTRODUCTION
TABLE 29 NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
11.2 HOSPITALS & CLINICS
11.2.1 INCREASING USE OF NEEDLE-LESS VACCINATION TO DRIVE ADOPTION
TABLE 30 NEEDLE-FREE INJECTION SYSTEM MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2019–2026 (USD MILLION)
11.3 HOMECARE SETTINGS
11.3.1 GROWING NEED FOR HOME SELF-ADMINISTRATION AND RISING GERIATRIC POPULATION TO DRIVE MARKET GROWTH
TABLE 31 NEEDLE-FREE INJECTION SYSTEM MARKET FOR HOMECARE SETTINGS, BY COUNTRY, 2019–2026 (USD MILLION)
11.4 RESEARCH LABORATORIES
11.4.1 GROWING RESEARCH OF DRUG TESTING ON ANIMALS TO DRIVE MARKET GROWTH
TABLE 32 NEEDLE-FREE INJECTION SYSTEM MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
11.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.5.1 INCREASING FOCUS ON BIOLOGICS DELIVERY RESEARCH TO DRIVE USAGE
TABLE 33 NEEDLE-FREE INJECTION SYSTEM MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
11.6 OTHER END USERS
TABLE 34 NEEDLE-FREE INJECTION SYSTEM MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
12 NEEDLE-FREE INJECTION SYSTEM MARKET, BY REGION (Page No. – 111)
12.1 INTRODUCTION
FIGURE 28 US TO DOMINATE NEEDLE-FREE INJECTION SYSTEM MARKET DURING FORECAST PERIOD
TABLE 35 NEEDLE-FREE INJECTION SYSTEM MARKET, BY REGION, 2019–2026 (USD MILLION)
12.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET SNAPSHOT
TABLE 36 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 37 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 38 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 39 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 40 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 41 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 42 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
12.2.1 US
12.2.1.1 US to account for the largest share of needle-free injection system market
TABLE 43 US: MACROECONOMIC INDICATORS
TABLE 44 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 45 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 46 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 47 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 48 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 49 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
12.2.2 CANADA
12.2.2.1 Availability of research funding and implementation of favorable government initiatives to drive market growth
TABLE 50 CANADA: MACROECONOMIC INDICATORS
TABLE 51 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 52 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 53 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 54 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 55 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 56 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
12.3 EUROPE
FIGURE 30 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET SNAPSHOT
TABLE 57 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 58 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 59 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 60 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 61 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 62 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 63 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
12.3.1 GERMANY
12.3.1.1 Increasing demand for self-injection devices to drive market demand
TABLE 64 GERMANY: MACROECONOMIC INDICATORS
TABLE 65 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 66 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 67 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 68 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 69 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 70 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
12.3.2 FRANCE
12.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth
TABLE 71 FRANCE: MACROECONOMIC INDICATORS
TABLE 72 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 73 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 74 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 75 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 76 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 77 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
12.3.3 UK
12.3.3.1 Increasing incidence of chronic diseases and rising prevalence of obesity to drive market growth
TABLE 78 UK: MACROECONOMIC INDICATORS
TABLE 79 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 80 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 81 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 82 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 83 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 84 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
12.3.4 ITALY
12.3.4.1 Increasing geriatric population and prevalence of chronic diseases to drive market growth
TABLE 85 ITALY: MACROECONOMIC INDICATORS
TABLE 86 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 87 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 88 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 89 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 90 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 91 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
12.3.5 SPAIN
12.3.5.1 Increasing prevalence of chronic diseases and technological advancement to drive market growth
TABLE 92 SPAIN: MACROECONOMIC INDICATORS
TABLE 93 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 94 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 95 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 96 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 97 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 98 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
12.3.6 REST OF EUROPE
TABLE 99 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 100 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 101 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 102 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 103 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 104 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
12.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: NEEDLE-FREE INJECTION SYSTEM MARKET SNAPSHOT
TABLE 105 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 106 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 107 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 108 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 109 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 110 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 111 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
12.4.1 JAPAN
12.4.1.1 Increasing geriatric population and higher adoption advance technology to drive market growth
TABLE 112 JAPAN: MACROECONOMIC INDICATORS
TABLE 113 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 114 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 115 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 116 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 117 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 118 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
12.4.2 CHINA
12.4.2.1 Growing prevalence of lifestyle-related and chronic diseases to drive market growth
TABLE 119 CHINA: MACROECONOMIC INDICATORS
TABLE 120 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 121 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 122 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 123 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 124 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 125 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
12.4.3 INDIA
12.4.3.1 Collaboration with key players in needle-free injections to drive market growth
TABLE 126 INDIA: MACROECONOMIC INDICATORS
TABLE 127 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 128 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 129 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 130 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 131 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 132 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
12.4.4 REST OF ASIA PACIFIC
TABLE 133 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 134 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 135 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 136 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 137 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 138 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
12.5 LATIN AMERICA
TABLE 139 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 140 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 141 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 142 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 143 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 144 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
12.6 MIDDLE EAST & AFRICA
12.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TO DRIVE MARKET GROWTH
TABLE 145 AFRICA: MACROECONOMIC INDICATORS
TABLE 146 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 147 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 148 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 149 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION)
TABLE 150 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 151 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION)
13 COMPETITIVE LANDSCAPE (Page No. – 180)
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE NEEDLE-FREE INJECTION SYSTEM MARKET
13.4 NEEDLE-FREE INJECTION SYSTEM MARKET RANKING
13.5 COMPANY EVALUATION QUADRANT
FIGURE 32 NEEDLE-FREE INJECTION SYSTEM MARKET: COMPANY EVALUATION MATRIX, 2020
13.5.1 STARS
13.5.2 PERVASIVE PLAYERS
13.5.3 EMERGING LEADERS
13.5.4 PARTICIPANTS
13.6 COMPETITIVE LEADERSHIP MAPPING FOR SMES & START-UPS
FIGURE 33 NEEDLE-FREE INJECTION SYSTEM MARKET: COMPANY EVALUATION MATRIX FOR SMES & START-UP
13.6.1 PROGRESSIVE COMPANIES
13.6.2 DYNAMIC COMPANIES
13.6.3 STARTING BLOCKS
13.6.4 RESPONSIVE COMPANIES
13.7 COMPETITIVE BENCHMARKING
13.7.1 OVERALL COMPANY FOOTPRINT
TABLE 153 OVERALL COMPANY FOOTPRINT (25 COMPANIES)
TABLE 154 COMPANY FOOTPRINT: BY-PRODUCTS (25 COMPANIES)
TABLE 155 COMPANY FOOTPRINT: BY TECHNOLOGY (25 COMPANIES)
TABLE 156 COMPANY FOOTPRINT: BY TYPE (25 COMPANIES)
TABLE 157 COMPANY FOOTPRINT: BY SITE OF DELIVERY (25 COMPANIES)
TABLE 158 COMPANY FOOTPRINT: BY APPLICATION (25 COMPANIES)
13.8 COMPETITIVE SCENARIO
13.8.1 PRODUCT LAUNCHES & APPROVALS
13.8.2 DEALS
TABLE 159 DEALS (2019–2021)
13.8.3 EXPANSIONS
TABLE 160 EXPANSIONS (2018)
14 COMPANY PROFILES (Page No. – 195)
14.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 PHARMAJET
TABLE 161 PHARMAJET: BUSINESS OVERVIEW
14.1.2 PORTAL INSTRUMENTS
TABLE 162 PORTAL INSTRUMENTS: BUSINESS OVERVIEW
14.1.3 MEDICAL INTERNATIONAL TECHNOLOGY INC.(MIT)
TABLE 163 MEDICAL INTERNATIONAL TECHNOLOGY INC: BUSINESS OVERVIEW
14.1.4 NUGEN MEDICAL DEVICES
TABLE 164 NUGEN MEDICAL DEVICES: BUSINESS OVERVIEW
14.1.5 CROSSJECT SA
TABLE 165 CROSSJECT SA: BUSINESS OVERVIEW
14.1.6 BIOJECT MEDICAL TECHNOLOGIES INC. (ACQUIRED BY INOVIO PHARMACEUTICALS, INC.)
TABLE 166 BIOJECT MEDICAL TECHNOLOGIES INC.: BUSINESS OVERVIEW
14.1.7 ANTARES PHARMA
TABLE 167 ANTARES PHARMA: BUSINESS OVERVIEW
FIGURE 34 ANTARES PHARMA: COMPANY SNAPSHOT
14.1.8 INJEX PHARMA GMBH
TABLE 168 INJEX PHARMA GMBH: BUSINESS OVERVIEW
14.1.9 NATIONAL MEDICAL PRODUCTS, INC.
TABLE 169 NATIONAL MEDICAL PRODUCTS, INC.: BUSINESS OVERVIEW
14.1.10 ZEALAND PHARMA A/S.
TABLE 170 ZEALAND PHARMA A/S: BUSINESS OVERVIEW
14.2 OTHER PLAYERS
14.2.1 PENJET CORPORATION
TABLE 171 PENJET CORPORATION: BUSINESS OVERVIEW
14.2.2 ENESI PHARMA LIMITED
14.2.3 INTEGRIMEDICAL LLC
TABLE 173 INTEGRIMEDICAL LLC: BUSINESS OVERVIEW
14.2.4 AKRA DERMOJET
TABLE 174 AKRA DERMOJET: BUSINESS OVERVIEW
14.2.5 D’ANTONIO CONSULTANTS INTERNATIONAL, INC.
TABLE 175 D’ANTONIO CONSULTANTS INTERNATIONAL, INC: BUSINESS OVERVIEW
14.2.6 BASCO INDIA
TABLE 176 BASCO INDIA: BUSINESS OVERVIEW
14.2.7 MIKA MEDICAL CO.
TABLE 177 MIKA MEDICAL CO.: BUSINESS OVERVIEW
14.2.8 MADA MEDICAL PRODUCTS, INC.
TABLE 178 MADA MEDICAL PRODUCTS, INC.: BUSINESS OVERVIEW
14.2.9 VAXXAS
TABLE 179 VAXXAS: BUSINESS OVERVIEW
14.2.10 GUANGZHOU MEDSINGLONG MEDICAL EQUIPMENT CO., LTD
TABLE 180 GUANGZHOU MEDSINGLONG MEDICAL EQUIPMENT CO., LTD: BUSINESS OVERVIEW
14.2.11 QUINOVARE
TABLE 181 QUINOVARE: BUSINESS OVERVIEW
14.2.12 TAPEMARK
TABLE 182 TAPEMARK: BUSINESS OVERVIEW
14.2.13 THERAJECT
TABLE 183 THERAJECT: BUSINESS OVERVIEW
14.2.14 ZOSANO PHARMA
TABLE 184 ZOSANO PHARMA: BUSINESS OVERVIEW
14.2.15 CORIUM
TABLE 185 CORIUM: BUSINESS OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15 APPENDIX (Page No. – 229)
15.1 DISCUSSION GUIDE
15.2 INDUSTRY INSIGHTS
15.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.4 AVAILABLE CUSTOMIZATIONS
15.5 RELATED REPORTS
15.6 AUTHOR DETAILS